Candel Therapeutics (CADL) Shares Outstanding (2020 - 2025)

Candel Therapeutics has reported Shares Outstanding (Entity) for 6 years, with the latest figure at $55.0 million in Q4 2025.

• Quarterly Shares Outstanding (Entity) rose 73.7% year-over-year to $55.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $55.0 million (up 73.7% YoY) and the FY2025 annual result came in at $55.0 million, up 73.7% from the prior year.
• Shares Outstanding (Entity) held at $55.0 million in Q4 2025 per CADL's latest filing, from $55.0 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $55.0 million in Q4 2025 and troughed at $11.7 million in Q1 2021.
• A 5-year average of $31.8 million and a median of $29.0 million in 2022 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) soared 147.31% in 2022, then grew 0.1% in 2023.
• Over 5 years, Shares Outstanding (Entity) stood at $18.9 million in 2021, then soared by 53.88% to $29.0 million in 2022, then grew by 0.59% to $29.2 million in 2023, then grew by 8.43% to $31.7 million in 2024, then soared by 73.7% to $55.0 million in 2025.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $55.0 million, $55.0 million, and $55.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.